Amgen Inc.
Key numbers
What the whole company is worth on the stock market.
Price ÷ last year's profit per share. Higher means investors pay more for each $1 of profit.
The same ratio using next year's expected profit.
How much the stock swings compared with the market: 1 moves like the market, 1.5 moves 50% more.
Yearly dividend as a share of the price.
What analysts say
34 analysts
Recent analyst actions
Financial health
Nine checks of profitability, debt and efficiency. 7–9 strong, 4–6 average, 0–3 weak.
A bankruptcy-risk score. Above 3 is the safe zone, 1.8–3 grey, below 1.8 distress.
Profitability and debt
Short-term assets ÷ short-term debts. Below 1 means more due within a year than on hand.
Fair value (DCF model)
A discounted-cash-flow model: what future cash flows are worth today. It is a model, not a promise.
Compared with similar companies
The company next to its sector peers.
| Company | Price | P/E | P/B | Market value |
|---|---|---|---|---|
| LLYEli Lilly and Company | 1,182.62 | 41.6 | 38.3 | $1.11T |
| JNJJohnson & Johnson | 263.73 | 29.9 | 6.1 | $630.04B |
| ABBVAbbVie Inc. | 281.12 | 77.4 | 94.4 | $488.55B |
| MRKMerck & Company, Inc. | 145.45 | 113.2 | 5.0 | $359.22B |
| UNHUnitedHealth Group Incorporated | 378.52 | 24.1 | 3.2 | $340.46B |
| TMOThermo Fisher Scientific Inc | 662.24 | 34.9 | 4.1 | $243.30B |
| AMGNAmgen Inc. | 417.57 | 25.7 | 20.4 | $224.29B |
| ABTAbbott Laboratories | 101.82 | 31.8 | 4.2 | $172.35B |
| PFEPfizer, Inc. | 28.40 | 37.2 | 1.6 | $161.19B |
| BMYBristol-Myers Squibb Company | 57.58 | 13.0 | 5.9 | $120.77B |
| Sector average | 42.9 | 18.3 |
About the company
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metasta…
Data: Elcaro Core (Yahoo Finance, Binance, Treasury) · Information, not investment advice.